-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3881 Altered Cerebral Functional Connectivity in Patients with Sickle Cell Disease

Program: Oral and Poster Abstracts
Session: 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Sickle Cell Disease, Clinical Research, Hemoglobinopathies, Diseases, Immune mechanism, Patient-reported outcomes, Technology and Procedures, Study Population, Human, Imaging
Monday, December 9, 2024, 6:00 PM-8:00 PM

Apeksha Sridhar, MSc1*, Eric Ichesco, BS2*, Andrew Q Pucka, BS3*, Andrew RW O'Brien, MD4, Steven E Harte, PhD2*, Richard E Harris, PhD1,5* and Ying Wang, MD, PhD3,4

1School of Medicine, Susan Samueli Integrative Health Institute, University of California, Irvine, Irvine, CA
2Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI
3Department of Anesthesia, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN
4Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN
5Department of Anesthesiology and Perioperative Care, University of California at Irvine, Irvine, CA

Background: Sickle cell disease (SCD) is a genetic disorder characterized by chronic pain, inflammation, and recurrent vaso-occlusive crises (VOCs) associated with extremely painful episodes. Pain in SCD is often debilitating, impacting quality of life (QoL). Prior studies have identified altered functional connectivity (FC) in SCD, primarily through resting-state FC analyses. However, the mechanisms underlying pain in SCD during active pain states remain underexplored compared to other chronic pain disorders. Pain in SCD is unique as it involves both nociceptive and neuropathic components due to ongoing hemolysis and ischemia-reperfusion injury. Our study aimed to address this gap by examining functional Magnetic Resonance Imaging (fMRI) FC during evoked experimental pain, focusing on the primary sensory cortices (S1) and Default Mode Network (DMN) due to their roles in pain integration and modulation. Additionally, we investigated the relationship of pain-evoked FC with clinical pain outcomes and pain-related quality of life in SCD patients.

Methods: We examined whole-brain group differences in evoked-pain FC between the S1 leg area and DMN in adult SCD patients aged18-73 (n = 18 total, n=11 females) compared to matched healthy controls (HCs, n = 16). Participants underwent fMRI scans during tonic pressure pain stimulation applied via a computerized cuff on the left gastrocnemius muscle. We selected the S1 leg area and DMN as primary seed regions, and seed-to-whole-brain connectivity maps were constructed to analyze group differences in FC. Pressure pain tolerance (PPTol) was assessed at the dominant-side upper trapezius muscle, providing an experimental measure of pain sensitivity (higher PPTol suggests lower pain sensitivity). Clinical pain outcomes included the Brief Pain Inventory (BPI) Pain Severity, Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity, and PROMIS Pain Interference scores. The impact of SCD and pain on QoL was measured using the Pediatric Quality of Life Inventory (PedsQLTM) SCD module (adult version), with higher scores indicating better QoL and fewer pain-related difficulties. Pearson correlations were computed between FC and these clinical measures in SCD patients to explore the relationship between brain connectivity and pain perception and management.

Results: SCD patients exhibited reduced FC during the pressure pain stimulation between the left S1 leg area and the thalamus, both left (T=3.37, pFWE=0.04) and right (T=3.37, pFWE=0.03) hemispheres, compared to HCs. Additionally, individuals with SCD showed reduced FC between the DMN and the right prefrontal cortex (PFC) (T=3.37, pFWE<0.01) compared to HCs. In SCD, the FC between the DMN and right PFC showed a marginal negative correlation with PPTol (r=-0.46, p=0.06), indicating that decreased FC was associated with increased pain tolerance. Reduced FC between the DMN and right PFC was also associated with lower levels of clinical pain: BPI Pain Severity (r=0.60, p=0.012), PROMIS Pain Intensity (r=0.70, p<0.01), and PROMIS Pain Interference scores (r=0.62, p=0.01) in SCD. A negative association was found between FC in the same regions and PedsQL scores (r=-0.78, p<0.001), indicating that decreased FC was linked to greater QoL in SCD.

Conclusions: Our results demonstrate altered FC in SCD patients compared to HCs, with differences observed in regions implicated in pain processing. The unexpected direction of the correlations, where patients exhibited reduced FC compared to controls, despite increased FC being linked to worse pain outcomes, implicates different underlying pain pathways. The reduced FC between the S1 leg area and thalamus might be related to descending pathways resulting from recurrent VOCs and chronic opioid use, which are common in SCD patients. Concurrently, the decreased FC between the DMN and PFC may reduce cognitive focus on pain, potentially increasing pain tolerance. Our findings are novel but must be validated through our continuous investigation with a larger sample size. Potential confounders such as chronic transfusion, hydroxyurea, and other concurrent treatments for managing pain may also impact the FC and should be explored in future studies. Neuroimaging techniques such as fMRI are important tools for advancing the understanding of pain mechanisms and facilitating diagnostics, prognostics, and pain management outcomes in SCD.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH